We are live on
!
Find out more
FLAM
First Light Asset Management Portfolio holdings
AUM
$1.12B
1-Year Est. Return
114.45%
This Fund
S&P 500
This Quarter
Est. Return
+6.22%
1 Year Est. Return
+114.45%
3 Year Est. Return
+266.49%
5 Year Est. Return
+454.92%
10 Year Est. Return
+8,470.94%
AUM
$212M
AUM Growth
+$16.7M
(+8.5%)
Cap. Flow
+$11.9M
Cap. Flow
% of AUM
5.62%
Top 10 Holdings %
Top 10 Hldgs %
46.87%
Holding
65
New
3
Increased
31
Reduced
4
Closed
4
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
LHCG
LHC Group LLC
LHCG
|
+$4.64M |
| 2 |
AMAG
AMAG Pharmaceuticals
AMAG
|
+$4.57M |
| 3 |
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
|
+$4.24M |
| 4 |
ESPR
Esperion Therapeutics
ESPR
|
+$1.95M |
| 5 |
AtriCure
ATRC
|
+$1.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
NVDQ
Novadaq Technologies Inc.
NVDQ
|
+$3.97M |
| 2 |
Ligand Pharmaceuticals
LGND
|
+$3.7M |
| 3 |
LCI
Lannett Company, Inc.
LCI
|
+$3.37M |
| 4 |
STAAR Surgical
STAA
|
+$2.53M |
| 5 |
NeoGenomics
NEO
|
+$1.16M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 82.38% |
| 2 | Energy | 2.37% |
| 3 | Consumer Staples | 0.82% |
| 4 | Financials | 0.31% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
AtriCure
ATRC
$1.92B
| $19M | 8.96% |
772,861
+67,291
| +10% | +$1.5M |
|
|
2
NeoGenomics
NEO
$1.96B
| $14.8M | 6.97% |
2,737,943
-224,081
| -8% | -$1.16M |
|
|
AKRX
3
DELISTED
Akorn Inc
AKRX
| $12.2M | 5.76% |
280,098
+24,387
| +10% | +$1.13M |
|
|
SRGA
4
DELISTED
Surgalign Holdings, Inc. Common Stock
SRGA
| $11.1M | 5.21% |
57,113
+5,024
| +10% | +$933K |
|
5
Harvard Bioscience
HBIO
$27.5M
| $9.74M | 4.58% |
170,802
+14,552
| +9% | +$828K |
|
|
AMAG
6
DELISTED
AMAG Pharmaceuticals
AMAG
| $7.83M | 3.68% |
113,368
+72,673
| +179% | +$4.57M |
|
|
NXTM
7
DELISTED
NxStage Medical Inc.
NXTM
| $6.44M | 3.03% |
450,958
+39,241
| +10% | +$665K |
|
|
OXFD
8
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
| $6.21M | 2.92% |
448,365
+38,215
| +9% | +$517K |
|
|
ARRY
9
DELISTED
Array Biopharma Inc
ARRY
| $6.12M | 2.88% |
849,374
+73,648
| +9% | +$543K |
|
|
TEAR
10
DELISTED
TearLab Corporation
TEAR
| $6.1M | 2.87% |
301,787
+6,739
| +2% | +$158K |
|
|
SPNC
11
DELISTED
Spectranetics Corp
SPNC
| $5.73M | 2.7% |
249,187
+21,570
| +9% | +$602K |
|
12
Insmed
INSM
$21.4B
| $5.65M | 2.66% |
231,471
+21,405
| +10% | +$486K |
|
|
TLGT
13
DELISTED
Teligent, Inc
TLGT
| $5.55M | 2.61% |
88,096
+7,470
| +9% | +$505K |
|
14
Omnicell
OMCL
$1.61B
| $5.54M | 2.61% |
146,921
+13,063
| +10% | +$476K |
|
15
Veracyte
VCYT
$3.7B
| $5.37M | 2.53% |
482,263
+42,260
| +10% | +$416K |
|
|
LHCG
16
DELISTED
LHC Group LLC
LHCG
| $5.03M | 2.37% |
+131,467
| New | +$4.64M |
|
|
17
Ligand Pharmaceuticals
LGND
$5.76B
| $4.96M | 2.33% |
78,731
-67,758
| -46% | -$3.7M |
|
18
Celldex Therapeutics
CLDX
$2.99B
| $4.67M | 2.2% |
12,356
+1,080
| +10% | +$429K |
|
|
ELGX
19
DELISTED
Endologix Inc
ELGX
| $4.67M | 2.2% |
30,460
+2,734
| +10% | +$451K |
|
20
Bio-Techne
TECH
$11.2B
| $4.62M | 2.17% |
187,684
+15,540
| +9% | +$388K |
|
|
ENZ
21
DELISTED
Enzo Biochem, Inc.
ENZ
| $4.36M | 2.05% |
1,439,330
+115,008
| +9% | +$323K |
|
|
CYNA
22
DELISTED
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
| $4.21M | 1.98% |
+258,606
| New | +$4.24M |
|
23
QuidelOrtho
QDEL
$1.14B
| $3.96M | 1.87% |
172,668
+15,003
| +10% | +$349K |
|
24
AngioDynamics
ANGO
$611M
| $3.88M | 1.83% |
236,692
+20,909
| +10% | +$347K |
|
25
LeMaitre Vascular
LMAT
$2.32B
| $3.87M | 1.82% |
320,768
+28,649
| +10% | +$282K |
|
Similar funds
AIM
MTCM
CNC
C
RIM
CT
SL
HH
First Light Asset Management's Q2 2015 Portfolio in Review
As of Q2 2015, First Light Asset Management held 65 positions worth $212M, up 8.5% from $196M the previous quarter. Its ten largest holdings account for 47% of the portfolio.
First Light Asset Management deployed $11.9M of net new capital in Q2 2015, opening 3 new positions and adding to 31 existing holdings. Its largest new stake was LHC Group LLC: 131,467 shares worth $5.03M.
By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 89% a quarter earlier, followed by Energy and Consumer Staples.
On the sell side, the largest reduction was Ligand Pharmaceuticals, an estimated $3.7M trimmed.
- First Light Asset Management's largest Q2 2015 buy was LHC Group LLC: 131,467 shares worth $5.03M.
- First Light Asset Management added most to AMAG Pharmaceuticals in Q2 2015, an estimated $4.57M increase.
- First Light Asset Management's biggest Q2 2015 reduction was Ligand Pharmaceuticals, cutting an estimated $3.7M.
- First Light Asset Management fully exited Novadaq Technologies Inc. in Q2 2015, selling an estimated $3.97M.
- First Light Asset Management's ten largest holdings make up 47% of its $212M portfolio in Q2 2015.
- First Light Asset Management opened 3 new positions and closed 4 in Q2 2015.
- First Light Asset Management's portfolio value rose 8.5% quarter-over-quarter to $212M.
Based on First Light Asset Management's 13F filing for Q2 2015, filed 14 Aug 2015.